Hemex Health

Hemex Health is a private, commercial-stage diagnostics company with its Gazelle platform already deployed in over 40 countries, though not yet cleared for sale in the United States. The portable, battery-powered platform integrates microchip electrophoresis and fluorescent immunoassay (FIA) technologies to provide quantitative results for hemoglobin variants and ferritin levels in minutes. The company recently received FDA Breakthrough Device Designation for its Hb Variant Test, signaling significant regulatory progress and potential for U.S. market entry. Its core mission is to address the vast unmet need for accessible, point-of-care testing for inherited blood disorders and anemia worldwide.

The Gazelle platform integrates paper-based microchip electrophoresis and fluorescent immunoassay (FIA) technologies into a portable, battery-powered point-of-care device. It uses AI-driven algorithms for automated result interpretation and is designed for a expandable menu of quantitative blood tests.

Hemex competes in the point-of-care hematology diagnostics space. For sickle cell, competitors range from lab-based HPLC systems to other POC devices like the Sickle SCAN™ (BioMedomics) and HemoTypeSC™ (Silver Lake Research). In ferritin testing, it competes with central lab immunoassays and a few other POC quantitative ferritin devices. Gazelle's key differentiators are its quantitative results, multi-test platform capability, and proven ruggedness for low-resource settings.